Entest BioMedical Inc. Declares Dividend of Preferred Stock
10 Februar 2012 - 10:10PM
Business Wire
Entest BioMedical Inc. (OTCQB: ENTB), a veterinary biotechnology
company and operator of veterinary hospitals, today announced the
declaration of a dividend of one share of the Company’s Series B
Preferred Stock for every eight shares of Entest BioMedical, Inc.
Common Stock owned as of the Record Date. The Record date is
February 21, 2012 and the dividend is set to be paid on or about
February 28, 2012.
The Company’s Series B Preferred Stock is a newly authorized
series of preferred stock ranking senior to the Company’s common
stock as to dividends, distributions or as to distributions of
assets upon liquidation, dissolution, or winding up of the
Company.
Holders of Series B Preferred Stock will be entitled to receive,
when and if declared by the board of directors of the Company out
of funds of the Company legally available, noncumulative cash
dividends of $0.02 per quarter per Series B Preferred Share as well
as additional dividends equal to dividends paid to common
shareholders.
Upon any liquidation, dissolution, or winding up of the Company
the holders of Series B Preferred Stock shall be entitled to
receive out of the assets of the Company an amount equal to $0.10
per share of Series B Preferred Stock plus all declared and unpaid
dividends before any distribution or payment may be made to any of
the holders of Common Stock or any other series of preferred
stock.
A copy of The Certificate of Designations establishing the
voting powers, designations, preferences, limitations, restrictions
and the relative rights of the Series B Preferred Stock has been
filed as an exhibit attached to the Company’s current report on
Form 8-K filed with the Securities and Exchange Commission (SEC) on
February 8, 2012 and can be found on the SEC's website at
www.sec.gov.
About Entest BioMedical Inc.
Entest BioMedical Inc. (http://www.entb.net/) is a veterinary
biotechnology company focused on developing therapies that harness
the animal's own reparative / immunological mechanisms. The
Company's products include an immuno-therapeutic cancer vaccine for
canines (ImenVax™). ImenVax™ is less invasive and less traumatic in
treating cancer. Additionally, the Company serves as the contract
research organization conducting a pilot study on a stem cell based
canine osteoarthritis treatment (developed by RenovoCyte LLC)
utilizing a ‘universal donor’ stem cell. Entest is also building a
network of veterinary hospitals (present locations include one in
Santa Barbara, CA and another in Eugene, OR) – which serve as
distribution channels for its products.
Forward-Looking Statements
This news release may contain forward-looking statements.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
statements. The risks and uncertainties to which forward-looking
statements are subject include, but are not limited to, the effect
of government regulation, competition and other material risks.
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Entest (CE) (USOTC:ETNI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
